Primary or secondary prevention of HIV-associated histoplasmosis during the early antiretrovirals for all era.

Given the high incidence of disseminated histoplasmosis in the profoundly immunosuppressed, the question of primary prophylaxis against histoplasmosis for patients with advanced HIV in endemic areas should be reconsidered until I Histoplasma i antigen tests become widely available. Although most studies actually concern symptomatic patients, the natural history of HIV-associated progressive disseminated histoplasmosis is presumably often gradual; as the immunity gradually declines, the fungal burden gradually increases, and the intensity of symptoms, especially those impairing vital functions, grows. Shows that in the past decade, the yearly number patients with disseminated histoplasmosis declined and that the delay between HIV diagnosis and histoplasmosis diagnosis also declined. Nevertheless, since the "treat all" strategy in 2016, there were 17 histoplasmosis cases, 5/17 were patients on HAART and 3/5 developed histoplasmosis over a year after their HIV diagnosis. [Extracted from the article]